.jpeg)
Median survival time for leukemia treated with Duvelisib
Duvelisib (Duvelisib) has shown certain efficacy in the treatment of leukemia. However, the specific median survival may vary depending on the patient's specific condition, response to treatment, and other factors. In some clinical trials, duveliside has shown an increase in median survival in patients with leukemia, but specific numbers may vary depending on the study design and patient population. It should be noted that the median survival time is only a statistical indicator used to describe the median survival time of a group of patients. It does not accurately predict how long each patient will survive because each patient's condition and response are unique.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
